[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Petrescu A, Dobrea C, Vasilică M, Andrei F, Niculescu L: Primary malignant lymphoma of the testis. Rom J Morphol Embryol; 2005;46(2):83-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the testis.
  • Primary testicular lymphomas are rare entities representing 1-2% of non-Hodgkin lymphoma (NHML) and 1-7% of malignant testicular tumors and they are the most common testicular tumors in men older than 50 years of age.
  • The age of patients was between 46 and 81 (with a mean of 52).
  • Orchectomy was performed as first therapeutic and diagnostic purpose.
  • All patients were clinically staged according to the Ann Arbor criteria in IE and IIID stage and received a doxorubicin based chemotherapy regimen (CHOP, MTX, CVP, and Leukeran).
  • A standard chemotherapy protocol has not been used because of reduced number of patients.
  • Alphafetoprotein was positive in seminal tubes and negative in tumor, NK1 in small lymphocyte and negative in tumor and L26 diffuse positive in tumor.
  • CONCLUSIONS: The diagnosis was of NHML in 6 cases and for 2 secondary involvement of hematopoietic malignancy (myeloid sarcoma and leukemia).
  • Lymphoma cases were typed using REAL classification as small and large B-cell lymphoma.
  • Unfavorable evolution with 6 months relapse and one death prove a more aggressive evolution of primitive testicular lymphoma.
  • [MeSH-major] Lymphoma / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286990.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


2. Ramani P, Ahmed S, Janaki VR: Primary extranodal non-Hodgkin's lymphoma of the oral cavity. Indian J Dermatol Venereol Leprol; 2004 May-Jun;70(3):172-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extranodal non-Hodgkin's lymphoma of the oral cavity.
  • Non-Hodgkin's lymphoma (NHL) belongs to a group of lymphoid neoplasms that is diverse in manner of presentation, response to therapy and prognosis.
  • A 55 year old woman presented with a swelling in the maxillary right alveolus and buccal vestibule.
  • There were no palpable lymph nodes.
  • Incisional biopsy of the lesion showed a dense lymphocytic infiltrate with formation of variably sized lymphoid follicles.
  • The infiltrate showed a mixed neoplastic lymphocyte composition which was suggestive of follicular mixed type of malignant B cell primary extranodal lymphoma.
  • The patient was treated with chemotherapy followed by radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642600.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Tanaka M, Matsuzaki J, Kitami K, Hirokawa M: [A case of primary malignant lymphoma of the pararectal space]. Hinyokika Kiyo; 2002 Sep;48(9):561-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of the pararectal space].
  • A large tumor was palpable by digital rectal examination.
  • Histopathological diagnosis was non-Hodgkin's malignant lymphoma (diffuse large B-cell type according to the new WHO classification).
  • The results of some examinations were compatible with the diagnosis of primary lymphoma of the pararectal space.
  • The patient underwent 2 courses of combination chemotherapy CHOP (consisting of cyclophosphamide, doxorubichin, vincristine, and prednisolone), and high-dose chemotherapy (ranimustine, etoposide, ifosfamide) with peripheral blood stem cell transplantation.
  • After high-dose chemotherapy, radiation therapy was performed since there was a possibility of residual tumor, and complete remission was achieved.
  • This is probably the first clinical case of malignant lymphoma of the pararectal space ever reported in the Japanese literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation. Rectal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402484.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


Advertisement
4. Guilarte M, Luengo O, Nogueiras C, Labrador-Horrillo M, Muñoz E, López A, Cardona V: Acquired angioedema associated with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol; 2008;18(2):126-30
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angioedema caused by C1 inhibitor deficiency is a rare disorder that may be either hereditary or acquired, the latter being mainly associated with lymphoproliferative disorders.
  • Due to a worsening of her symptoms she was reassessed and low levels of C1q and an abnormal lymphocyte count were detected.
  • Immunophenotyping of peripheral blood revealed 9% monoclonal lambda B cells with a follicular center phenotype.
  • The histopathology was consistent with a grade II follicular lymphoma stage IV-A.With chemotherapy, the hematologic disease was controlled and C1q levels returned to normal values.
  • This represents a rare case of a patient with hereditary angioedema who developed acquired angioedema due to a lymphoma that was associated with a reduction in the levels of C1q as her symptoms worsened.
  • [MeSH-major] Angioedema / etiology. Angioedemas, Hereditary / complications. Complement C1 Inactivator Proteins / deficiency. Lymphoma, Follicular / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Complement Activation. Complement C1 / genetics. Complement C1 / metabolism. Female. Humans. Lymphocyte Count. Middle Aged. Pedigree. Stanozolol / therapeutic use

  • Genetic Alliance. consumer health - Acquired Angioedema.
  • Genetic Alliance. consumer health - Hereditary angioedema.
  • Hazardous Substances Data Bank. STANOZOLOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447143.001).
  • [ISSN] 1018-9068
  • [Journal-full-title] Journal of investigational allergology & clinical immunology
  • [ISO-abbreviation] J Investig Allergol Clin Immunol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Complement C1; 0 / Complement C1 Inactivator Proteins; 0 / SERPING1 protein, human; 4R1VB9P8V3 / Stanozolol
  •  go-up   go-down


5. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J: Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol; 2000 Jan;11(1):115-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
  • Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3.
  • Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma).
  • Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10690400.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 80168379AG / Doxorubicin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Hamada S, Ito K, Kanbara T, Yoshii T, Sato K, Sumitomo M, Kimura F, Asano T: [A case of malignant lymphoma mimicking a seminal vesicle tumor]. Hinyokika Kiyo; 2010 Jul;56(7):393-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma mimicking a seminal vesicle tumor].
  • Abdominal computed tomography (CT) showed a mass 7 cm in diameter mimicking a seminal vesicle tumor and magnetic resonance imaging showed a heterogeneously enhanced mass with an unclear borderline to the rectum.
  • The differential diagnosis of the lesion included a tumor arising from a seminal vesicle, a local recurrence of rectal cancer, a rectal GIST, and a mesenchymal tumor.
  • Transrectal needle biopsy revealed non-Hodgkin's malignant lymphoma (diffuse large B cell lymphoma).
  • Chest and abdominal CT showed no specific findings except the lesion for the seminal vesicle lesion, but positron emission tomography showed accumulations in the gastrointestinal tract, pleura, and lymph nodes.
  • The patient was thus determined to have stage IV malignant lymphoma and was given two courses of combination chemotherapy including RCHOP.
  • [MeSH-major] Genital Neoplasms, Male / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Seminal Vesicles
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20724815.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Hartmann JT, Meisinger I, Kröber SM, Weisel K, Klingel K, Kanz L: Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. Haematologica; 2006 Dec;91(12 Suppl):ECR49
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
  • Human parvovirus B 19 is known as a virus causing erythema infectiosum, arthropathy, transient aplastic crisis and intrauterine fetal death.
  • Herein, we describe a 56-year old woman with a relapse of grade II follicular lymphoma who received a combined immunochemotherapy of rituximab, fludarabine and cyclophosphamide and subsequently developed a persistent parvovirus B19 infection.
  • Treatment with IVIG treatment resulted in normalization of peripheral blood counts within 7 weeks.
  • [MeSH-major] Anemia / etiology. Leukopenia / etiology. Lymphoma, Follicular / drug therapy. Parvoviridae Infections / complications. Parvovirus B19, Human / pathogenicity
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / virology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Female. Humans. Immunocompromised Host. Immunoglobulins, Intravenous / therapeutic use. Immunotherapy / adverse effects. Middle Aged. Prednisolone / administration & dosage. Recurrence. Rituximab. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives. Vincristine / administration & dosage. Viremia / blood. Viremia / complications

  • Genetic Alliance. consumer health - Persistent parvovirus infection.
  • MedlinePlus Health Information. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194655.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulins, Intravenous; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VAP-cyclo protocol
  •  go-up   go-down


8. Koike H, Morita T, Tamura Y: [Primary malignant lymphoma of the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2004 May;95(4):675-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant lymphoma of the urinary bladder: a case report].
  • We report a case of primary malignant lymphoma of the urinary bladder.
  • A 72-year old woman complaining of low abdominal pain was admitted to the Tone Central Hospital in February, 2001.
  • Macrohematuria appeared, and the submucosal tumor was observed by cystoscopy, and A Transurethral bladder biopsy led to a histopathological diagnosis of non-Hodgkin's malignant lymphoma (diffuse lymphoma, large-sized cell type, B-cell type).
  • Clinical stage was IE, but as soon, she was get bilateral hydronephrosis and bladder-ileum fistula.
  • The administration of 6-course CHOP chemotherapy had an excellent effect of disappearing the tumor, bilateral hydronephrosis, and bladder-ileum fistula.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Remission Induction. Stents. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198002.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Hatta C, Ogasawara H, Okita J, Kubota A, Ishida M, Sakagami M: Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification. Auris Nasus Larynx; 2001 Jan;28(1):55-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification.
  • OBJECTIVE: Although the Working Formulation is commonly used to classify NHL in Japan, it has been recognized as imperfect for primary extranodal lymphoma, especially for patients with sinonasal disease because of their histological characteristics.
  • The present study investigated the clinical characteristics and the prognosis of sinonasal lymphomas according to REAL classification.
  • METHODS: Fifty-three patients with non-Hodgkin's malignant lymphoma (NHL) of the sinonasal tract were treated between 1981 and 1997.
  • The age at clinical presentation was from 10 to 84 years (mean, 52.4 years).
  • According to the Ann Arbor system, there were 30 patients with Stage IE, 13 with Stage IIE, 4 with Stage IIIE, and 6 with Stage IVE lymphomas.
  • Statistical analysis was performed with a generalized Wilcoxon method.
  • RESULTS: All of the lymphomas showed a diffuse growth pattern.
  • Based on the origin of the tumor cells, the authors classified NHL of the sinonasal tract into five groups with the REAL classification of Japan: diffuse large B-cell lymphoma (22.6%), peripheral T-cell lymphomas (15.1%), angiocentric lymphoma (35.9%), other lymphomas and unclassified types.
  • Of 53 patients, 39 (73.6%) received chemotherapy and radiotherapy, eight patients received chemotherapy alone, and four patients received radiotherapy alone.
  • The cumulative 5-year survival rates were 28.5% for all of the types, 55.0% for diffuse large B-cell lymphoma, 33.3% for peripheral T-cell lymphoma, and 19.7% for angiocentric lymphoma.
  • Results suggest that conventional combined treatment (CHOP chemotherapy+radiotherapy) is ineffective for NHL of the sinonasal tract, and especially so for NHL in the nasal cavity, NHL with tumor cells with positive T-cell markers, NHL further than Stage IIE and NHL with B symptoms.
  • CONCLUSION:. (1) In light of this ineffectiveness, new therapies must be developed to improve patient outcome instead of the conventional combined treatment;.
  • (2) REAL classification is clear and useful for sinonasal lymphomas in Japan.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / classification. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11137364.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


10. Cavalot AL, Preti G, Vione N, Nazionale G, Palonta F, Fadda GL: Isolated primary non-Hodgkin's malignant lymphoma of the larynx. J Laryngol Otol; 2001 Apr;115(4):324-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated primary non-Hodgkin's malignant lymphoma of the larynx.
  • We report a case of glottic primary laryngeal lymphoma.
  • Although the head and neck region is a frequent site of origin of extranodal non-Hodgkin's lymphomas, laryngeal involvement is exceptional.
  • Including this case, about 90 primary laryngeal lymphomas have been reported in the literature.
  • Microscopic study showed a diffuse malignant lymphoma of high-grade malignancy (WF sub-division H).
  • A diffuse, large, B-cell-type NHL was diagnosed histopathologically.
  • The patient was treated with combination chemotherapy, including cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), which resulted in complete clinical remission after two courses.
  • Four courses of combination chemotherapy were subsequently performed, making a total of six courses of combination chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisolone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11276342.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Number-of-references] 28
  •  go-up   go-down


11. Tomita N, Kodama F, Oshima R, Hashimoto C, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y: Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma. Leuk Lymphoma; 2006 Jun;47(6):1041-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
  • Recently, the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen plus rituximab (R-CHOP) have been used widely to treat patients with follicular lymphoma.
  • We investigated a fixed scheme of combination chemotherapy protocol including CHOP, granulocyte colony stimulating factor (G-CSF) and rituximab (CHOP-GR) for patients with advanced-stage grade 1 or grade 2 follicular lymphoma in a phase II clinical trial, assessing enhancement of antibody-dependent cellular cytotoxicity of rituximab by G-CSF.
  • Twenty-one untreated patients received two courses of CHOP chemotherapy followed by four courses of CHOP-GR, including G-CSF (s.c.) on days 11 - 14 and rituximab on day 15.
  • Two patients, one with no response and subsequent allogeneic hematopoietic stem cell transplantation and one with progressive disease, died of lymphoma.
  • One patient refused to continue therapy, whereas two were rediagnosed and no longer met histologic criteria; these three patients were classified as nonresponders.
  • After a median observation time of 23 months, the 19 histologically assessable patients showed a 2-year progression-free survival rate of 82%, whereas 2-year overall survival was 95%.
  • Of seven patients with initial bulky mass, five responded to therapy.
  • Of 11 patients examined for bcl-2 translocation in peripheral blood or marrow by polymerase chain reaction (PCR), four were positive, whereas three of the four had complete remissions and converted to PCR negativity after therapy.
  • According to short-term observation, CHOP-GR is a safe and effective therapy for patients with advanced-stage follicular lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Synergism. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Rituximab. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840195.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Takahashi T, Hara T, Yoshikawa T, Shimomura Y, Tsurumi H, Yamada T, Tomita E, Moriwaki H: [Early transformation from follicular lymphoma to Burkitt lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1055-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early transformation from follicular lymphoma to Burkitt lymphoma].
  • We report a rare case of follicular lymphoma which rapidly showed transformation to the Burkitt type of lymphoma after a treatment consisting of chemotherapy and irradiation.
  • He was diagnosed as having follicular lymphoma (grade 2) (clinical stage IIIA) with complex karyotypic abnormalities involving t(14 ; 18)(q32 ;.
  • Initially he was followed as an outpatient without chemotherapy.
  • He underwent chemotherapy with 4 courses of CHOP regimen following irradiation therapy and a partial response was obtained.
  • Four months after initiation of the treatment, his disease recurred with numb chin syndrome.
  • Bone marrow aspiration revealed bone marrow involvement by lymphoma cells which had a Burkitt-like appearance.
  • In spite of salvage chemotherapy, the patient died in September 2001.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Salvage Therapy. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440764.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Bonnici A, Ruiner CE, St-Laurent L, Hornstein D: An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother; 2010 Sep;44(9):1504-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
  • OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).
  • CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively.
  • His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.
  • He developed a high fever (40.5 degrees C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment.
  • His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube.
  • DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal.
  • In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale.
  • CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.
  • [MeSH-major] Antiparkinson Agents / adverse effects. Enteral Nutrition / adverse effects. Food-Drug Interactions. Levodopa / adverse effects. Neuroleptic Malignant Syndrome / etiology
  • [MeSH-minor] Carbidopa / administration & dosage. Drug Therapy, Combination. Humans. Intensive Care Units. Length of Stay. Male. Middle Aged. Parkinson Disease / drug therapy

  • Genetic Alliance. consumer health - Neuroleptic malignant syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628041.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 46627O600J / Levodopa; MNX7R8C5VO / Carbidopa
  •  go-up   go-down


14. Spectre G, Gural A, Amir G, Lossos A, Siegal T, Paltiel O: Central nervous system involvement in indolent lymphomas. Ann Oncol; 2005 Mar;16(3):450-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in indolent lymphomas.
  • BACKGROUND: Central nervous system (CNS) involvement, a well-recognized complication of aggressive non-Hodgkin's lymphomas (NHL), has rarely been reported in indolent lymphomas.
  • Large series have reported this complication in 3% of indolent NHLs, generally following histological transformation.
  • PATIENTS AND METHODS: We retrospectively reviewed the disease characteristics and clinical course in seven patients (six females, one male) with indolent B-cell lymphomas who developed CNS involvement during various stages of their illness.
  • RESULTS: The median ages at diagnosis of systemic and CNS lymphoma were 60 and 63 years, respectively.
  • Histologies were: small lymphocytic lymphoma (two), follicular lymphoma grade I (two), follicular lymphoma grade II (two) and unclear low-grade histology (one).
  • Systemic lymphoma was found in all patients, all but one having bone marrow involvement.
  • Four patients had a transformation to high-grade histology.
  • Six patients were treated with systemic and intra-cerebrospinal fluid chemotherapy, and two received radiotherapy as well.
  • CONCLUSIONS: CNS involvement is a rare and unexpected complication of indolent NHL, which should be considered in the differential diagnosis of patients presenting with new neurological signs.
  • This condition is treatable and some patients have a long clinical course.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642707.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Agrawal A, Ofili G, Allan TL, Mann BS: Malignant lymphoma of uterus: a case report with a review of the literature. Aust N Z J Obstet Gynaecol; 2000 Aug;40(3):358-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of uterus: a case report with a review of the literature.
  • The female genital tract is rarely the initial manifestation site of malignant lymphomas.
  • Most genital lymphomas arise in the vagina or cervix while those of the uterine corpus are extremely rare.
  • Patients usually present with bleeding, abdominal or pelvic discomfort or back pain but, very infrequently, the tumours are discovered as a result of a routine examination.
  • Histopathology revealed non-Hodgkin's malignant lymphoma of the uterine corpus.
  • She subsequently had post-operative chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Fatal Outcome. Female. Humans. Postmenopause. Tomography, X-Ray Computed. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11065052.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] AUSTRALIA
  • [Number-of-references] 13
  •  go-up   go-down


16. Gualtieri CT, Johnson LG: Medications do not necessarily normalize cognition in ADHD patients. J Atten Disord; 2008 Jan;11(4):459-69
Hazardous Substances Data Bank. ATOMOXETINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medications do not necessarily normalize cognition in ADHD patients.
  • OBJECTIVE: Although ADHD medications are effective for the behavioral components of the disorder, little information exists concerning their effects on cognition, especially in community samples.
  • METHOD: A cross-sectional study of ADHD patients treated with three different ADHD drugs was conducted.
  • Patients' performance on a computerized neurocognitive screening battery was compared to untreated ADHD patients and normal controls (NML).
  • A total of 177 ADHD patients aged 10 to 18, achieved a favorable response to one of the following medications: Adderall XR (AMP), atomoxetine (ATMX), and Concerta (MPH-OROS) compared to 95 untreated ADHD patients and 101 NML.
  • CONCLUSION: Even with optimal treatment, based on parents' and teachers' opinions, subtle and not-so-subtle neurocognitive impairments persisted in the ADHD patients.
  • Some ADHD patients may require additional educational assistance, even in the face of successful medication treatment.
  • [MeSH-major] Adrenergic Uptake Inhibitors / pharmacology. Adrenergic Uptake Inhibitors / therapeutic use. Amphetamine / pharmacology. Amphetamine / therapeutic use. Attention Deficit Disorder with Hyperactivity / drug therapy. Central Nervous System Stimulants / pharmacology. Central Nervous System Stimulants / therapeutic use. Cognition / drug effects. Methylphenidate / pharmacology. Methylphenidate / therapeutic use. Propylamines / pharmacology. Propylamines / therapeutic use

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934180.001).
  • [ISSN] 1087-0547
  • [Journal-full-title] Journal of attention disorders
  • [ISO-abbreviation] J Atten Disord
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Central Nervous System Stimulants; 0 / Propylamines; 207ZZ9QZ49 / Methylphenidate; 57WVB6I2W0 / Atomoxetine Hydrochloride; CK833KGX7E / Amphetamine
  •  go-up   go-down


17. Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Valmorri L, Riccobon A, Ridolfi R: Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. J Clin Oncol; 2009 May 20;27(15_suppl):9042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment.
  • The combination of immunotherapies with standard treatments for cancer could represent a further chance for advanced melanoma patients.
  • In the literature, higher response rates than those normally obtained have been reported after second-line chemotherapy in patients with non small cell lung cancer pre-treated with vaccines and in patients with follicular B-cell lymphoma vaccinated with an anti-idiotype vaccine whilst in remission.
  • On the basis of this data, we reviewed and updated the clinical results of our dendritic cell based vaccine clinical trial in stage IV melanoma patients.
  • METHODS: From December 2002 to 2007, 24 pre-treated metastatic melanoma patients were vaccinated with mature DCs (mDCs) pulsed with autologous tumor lysate (ATL) and keyhole limpet hemocyanin (KLH) followed by a 5-day treatment with low-dose subcutaneous Interleukin-2.
  • RESULTS: We observed 2 complete response (CR), 2 mixed response (MR), 5 partial response (PR), 4 stable disease (SD) and 11 progressive disease (PD) (overall response (OS) 37.5%; clinical benefit 54.1%).
  • All 13 responders had delayed-type hypersensitivity (DTH) positivity to KLH, of whom 10 also showed positivity to the lysate.
  • Eleven (45.8%) of the 24 patients underwent further lines of treatment (5 chemotherapy [CT], 3 surgery [S], 4 biotherapy, 2 radiotherapy [RT] and 4 biochemotherapy [BioCT]) after stopping vaccination (8 due to progression and 3, in SD, because all of their lysate had been used).
  • Of these 11 patients, 2 obtained CR (1 RT, 1 S), 5 PR (3 BioCT, 2 S) for an OR of 63.6%, 1 SD (BioCT) and 3 showed PD as the best response to subsequent therapies, with a median OS of 30 months (range 16-52).
  • Of the 3 SD patients who were forced to stop vaccine treatment, 1 had CR following RT and 2 progressed.
  • CONCLUSIONS: Metastatic melanoma responds poorly to standard therapy, in particular after first-line treatment.
  • Vaccination could enhance clinical response to subsequent third- or fourth-line therapies, thus prolonging overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL: Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol; 2000 May;24(5):623-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases.
  • We report a retrospective clinicopathologic study of 108 primary thyroid gland lymphomas (PTLs), classified using the REAL and proposed WHO classification schemes.
  • All patients presented with a thyroid mass.
  • The PTLs were classified as marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or MZBL (n = 30), diffuse large B-cell lymphoma (DLBCL) with MZBL (n = 36), DLBCL without MZBL (n = 41), and follicle center lymphoma (FCL; n = 1).
  • Excluding the FCL, features of lymphomas of MALT-type were identified in all groups, despite a follicular architecture in 23% of cases.
  • Lymphocytic thyroiditis (LT) was identified in 94%.
  • Ninety-one percent of patients presented with stage IE or IIE disease, whereas 69% had perithyroidal soft tissue infiltration.
  • All patients were treated with surgical excision followed by adjuvant therapy (76%): chemotherapy (15%), radiation (19%), or a combination of radiation and chemotherapy (42%).
  • Statistically, stages greater than IE, presence of DLBCL, rapid clinical growth, abundant apoptosis, presence of vascular invasion, high mitotic rate, and infiltration of the perithyroidal soft tissue were significantly associated with death with disease.
  • In summary, PTLs typically occur in middle- to older-aged individuals as a thyroid mass, with a predilection for females.
  • Despite their histologic heterogeneity and frequent simulation of other lymphoma subtypes, virtually all PTLs are lymphomas of MALT-type arising in the setting of LT.
  • Mixed DLBCL and MZBL are common.
  • Overall, PTLs have a favorable outcome with appropriate therapy, but prognosis depends on both clinical stage and histology.
  • MZBL and stage IE tumors have an excellent prognosis, whereas tumors with a large cell component or DLBCL or stage greater than IE have the greatest potential for a poor outcome.
  • [MeSH-major] Lymphoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800981.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Peyromaure M, Van Glabeke E, Leblond V, Barrou B, Delcourt A, Richard F: [Primary lymphoma of the bladder]. Prog Urol; 2000 Dec;10(6):1208-11
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the bladder].
  • [Transliterated title] Le lymphome primitif de la vessie.
  • The authors report two cases of primary non-Hodgkin's malignant lymphoma of the bladder.
  • In contra with secondary site, which are not rare, primary malignant lymphomas of the bladder wall are exceptional.
  • Only histology provides the diagnosis.
  • Treatment is mainly based on chemotherapy.
  • [MeSH-major] Lymphoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11217561.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Manthorpe R, Bredberg A, Henriksson G, Larsson A: Progress and regression within primary Sjögren's syndrome. Scand J Rheumatol; 2006 Jan-Feb;35(1):1-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interest in aspects of primary SS including clinical manifestations, pathogenesis, aetiology, treatment, prognosis, etc has increased during the past three decades, the volume of scientific papers and the number of theses being the indicators.
  • The topics that are focused on in this review are: (a) clinical areas with subsections on signs and symptoms, terminology, predictors for development of non-Hodgkin malignant lymphoma (NHML) and prognosis, (b) treatment, (c) the Danger model (aetiopathogenesis) and (d) pathology, including immunoglobulin G4 (IgG4)-positive cells.
  • [MeSH-major] Sjogren's Syndrome / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Bromhexine / therapeutic use. Expectorants / therapeutic use. Humans. Immunologic Factors / therapeutic use. Models, Biological. Rituximab

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467033.001).
  • [ISSN] 0300-9742
  • [Journal-full-title] Scandinavian journal of rheumatology
  • [ISO-abbreviation] Scand. J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Expectorants; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; Q1J152VB1P / Bromhexine
  • [Number-of-references] 46
  •  go-up   go-down


21. Douglas A, Morris J: It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease. Age Ageing; 2006 Nov;35(6):640-1
MedlinePlus Health Information. consumer health - Fever.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
  • Neuroleptic malignant-like syndrome (NMLS) is a rare but life threatening and important complication because of the withdrawal of long-term l-Dopa therapy in Parkinson's disease patients.
  • In this case report, we review the pathophysiology, clinical features and treatment of this curable condition.
  • [MeSH-minor] Aged. Antiparkinson Agents / therapeutic use. Female. Humans. Levodopa / therapeutic use. Parkinson Disease / drug therapy

  • Genetic Alliance. consumer health - Neuroleptic malignant syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943262.001).
  • [ISSN] 0002-0729
  • [Journal-full-title] Age and ageing
  • [ISO-abbreviation] Age Ageing
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 46627O600J / Levodopa
  •  go-up   go-down


22. Iguchi T, Yokoyama K, Mitsuishi M, Chen CK, Ikeda Y, Okamoto S: [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1049-54
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma].
  • A 58-year-old man had a relapsed follicular lymphoma (Grade 2) and was treated with mitoxantrone, fludarabine and dexamethasone followed by rituximab, and achieved partial remission.
  • The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Three days after starting high-dose therapy, he developed a fever, and a chest X-ray revealed pneumonia in the right lower lung.
  • On day 43 he also developed hemorrhagic cystitis due to adenovirus type 11, and on day 49 positive CMV antigenemia was detected, which were treated supportively.
  • On day 75 he developed pneumonia probably due to Pneumocystis jirovecii, which was treated with sulfamethoxazole/trimethoprim.
  • The pulmonary tuberculosis resolved completely 4 months after starting the treatment, and the hemorrhagic cystitis and pneumocystis pneumonia resolved 1 month after the diagnosis.
  • [MeSH-major] Adenovirus Infections, Human / etiology. Cystitis / virology. Hemorrhage / etiology. Lymphoma, Follicular / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Tuberculosis, Pulmonary / etiology
  • [MeSH-minor] Adenoviridae Infections. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pneumocystis jirovecii. Pneumonia, Pneumocystis / etiology. Transplantation, Autologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440763.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Zuk E, Nowacki P, Fabian A: Guillain-Barre syndrome in patient with Burkitt's lymphoma and type 2 diabetes mellitus. Folia Neuropathol; 2001;39(4):281-4
MedlinePlus Health Information. consumer health - Guillain-Barre Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guillain-Barre syndrome in patient with Burkitt's lymphoma and type 2 diabetes mellitus.
  • Although peripheral neuropathies are commonly observed in patients with non-Hodgkin's malignant lymphomas (NHML), Guillain-Barre syndrome (GBS) belongs to the occasional complications of lymphoproliferative disorders.
  • It appears in less than 0.3 per cent of NHML.
  • It is worthy of note that in the reported case there occurred three independent risk factors of peripheral neuropathy: Burkitt's lymphoma, chemotherapy and type 2 diabetes mellitus.
  • Based on clinical course, EMG finding and neuropathological examination, in spite of normal cerebrospinal fluid protein content, GBS as a paraneoplastic disorder was diagnosed.
  • It was assumed that chemotherapy and diabetes mellitus conduced to severe neuropathy.


24. Reimer J, Kuhlmann A, Müller T: Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide. Parkinsonism Relat Disord; 2002 Dec;9(2):115-6
Genetic Alliance. consumer health - Neuroleptic malignant syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.
  • Neuroleptic malignant-like syndrome (NMLS) occurred after rapid switch from bromocriptine to pergolide in a Parkinsonian patient.
  • Long-term treatment with bromocriptine may thus have induced plastic changes in intracellular signal processing in the nigrostriatal system, which resulted in reduced dopaminergic efficacy of pergolide.
  • We recommend vigilant outpatient supervision during performance of rapid switchover from one dopamine agonist to another in advanced Parkinson's disease or in subjects with predisposing factors for onset of a neuroleptic malignant syndrome.
  • [MeSH-major] Bromocriptine / adverse effects. Neuroleptic Malignant Syndrome / diagnosis. Pergolide / adverse effects
  • [MeSH-minor] Dopamine Agonists / adverse effects. Dopamine Agonists / therapeutic use. Humans. Male. Middle Aged. Parkinson Disease / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12473402.001).
  • [ISSN] 1353-8020
  • [Journal-full-title] Parkinsonism & related disorders
  • [ISO-abbreviation] Parkinsonism Relat. Disord.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 24MJ822NZ9 / Pergolide; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


25. Gregor JI, Kilian M, Heukamp I, Kiewert C, Kristiansen G, Schimke I, Walz MK, Jacobi CA, Wenger FA: Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins Leukot Essent Fatty Acids; 2005 Aug;73(2):89-97
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
  • Furthermore, size and number of liver metastases per animal were determined and concentration of PGF1alpha, PGE2 and leukotrienes was measured in hepatic and pancreatic tissue.
  • Combined therapy (Celebrex+Zyflo) significantly decreased incidence, number and size of liver metastases.
  • Furthermore extra- and intrametastatic concentration of PGE2 was reduced by this treatment in hepatic tissue.
  • Single Cox-2-inhibition (Celebrex) decreased intrametastatic hepatic PGF1alpha and PGE2 concentration while PGF1alpha concentration was reduced in non-metastatic liver (nml).
  • Moreover 5-LOX-inhibition (Zyflo) decreased intrametastatic PGE2 concentration as well as PGF1alpha and PGE2 in nml.
  • In pancreatic carcinomas highest LT-concentration was found after combined treatment and this therapy group was the only one revealing a significantly higher amount of LTs in carcinomas compared to tumour-free tissue.
  • Hepatic LT-concentration was significantly lower in the control groups than in nml of the tumour groups.
  • Combination of Cox-2-inhibition and 5-Lox-inhibition might be a suitable adjuvant therapy to prevent liver metastasis in human ductal pancreatic adenocarcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Hydroxyurea / analogs & derivatives. Lipoxygenase Inhibitors / therapeutic use. Liver Neoplasms / prevention & control. Pancreatic Neoplasms / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Celecoxib. Cricetinae. Dinoprostone / analysis. Drug Therapy, Combination. Leukotrienes / analysis. Leukotrienes / biosynthesis. Liver / chemistry. Pancreas / chemistry. Prostaglandins / analysis. Prostaglandins / biosynthesis. Prostaglandins F / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964750.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Leukotrienes; 0 / Lipoxygenase Inhibitors; 0 / Prostaglandins; 0 / Prostaglandins F; 0 / Pyrazoles; 0 / Sulfonamides; 132880-11-6 / zileuton; 745-62-0 / prostaglandin F1; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


26. Heukamp I, Kilian M, Gregor JI, Neumann A, Jacobi CA, Guski H, Schimke I, Walz MK, Wenger FA: Effects of the antioxidative vitamins A, C and E on liver metastasis and intrametastatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology; 2005;5(4-5):403-9
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the antioxidative vitamins A, C and E on liver metastasis and intrametastatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters.
  • 2 and 6 were administered retinol, Gr.
  • No treatment was performed in Gr. 1 and 5.
  • Activities of glutathione-peroxidase (GSH-Px), superoxide dismutase (SOD) and concentration of thiobarbituric-acid-reactive substances (TBARS) were analyzed in hepatic tissue.
  • Activities of GSH-Px and SOD were increased and concentration of TBARS was decreased in NML and LiMe by all vitamins.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antioxidants / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Lipid Peroxidation / drug effects. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Animals. Ascorbic Acid / therapeutic use. Cricetinae. Disease Models, Animal. Glutathione Peroxidase / metabolism. Male. Mesocricetus. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Nitrosamines. Superoxide Dismutase / metabolism. Thiobarbituric Acid Reactive Substances / metabolism. Vitamin A / therapeutic use. Vitamin E / therapeutic use

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985764.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Nitrosamines; 0 / Thiobarbituric Acid Reactive Substances; 11103-57-4 / Vitamin A; 1406-18-4 / Vitamin E; 60599-38-4 / nitrosobis(2-oxopropyl)amine; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


27. Saigo K, Okumachi Y, Kondo S, Chinzei T, Okamura A, Takenokuchi M, Kawano S, Kumagai S: Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient. Leuk Lymphoma; 2006 Feb;47(2):353-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient.
  • A 48-year-old male patient with follicular lymphoma, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission.
  • After 9 months, the disease progressed and several chemotherapy agents, including three courses of rituximab combined with etoposide, sobuzoxane or methotrexate, only resulted in a stable disease response.
  • However, the fourth course of rituximab combined with a small dose of melphalan produced excellent results and the complete response continued for more than 15 months.
  • It is possible that these two drugs may act synergistically.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Melphalan / administration & dosage
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Drug Synergism. Humans. Male. Middle Aged. Remission Induction. Rituximab. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321871.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; Q41OR9510P / Melphalan
  •  go-up   go-down


28. Asahi A, Okamoto S, Matsushita H, Hattori Y, Takayama N, Ikeda Y: [Follicular lymphoma in two brothers]. Rinsho Ketsueki; 2001 May;42(5):408-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follicular lymphoma in two brothers].
  • Two brothers, whose parents had a history of exposure to atomic bomb radiation, developed non-Hodgkin's lymphoma.
  • The younger brother, a 48-year-old man, was diagnosed as having follicular small-cleaved cell lymphoma in October, 1996.
  • He had extranodal lymphoma involvement of the right kidney, bone marrow and skin, in addition to generalized lymphadenopathy.
  • He was treated with intermittent COP chemotherapy, and good control of the lymphoma was obtained.
  • The elder brother, aged 50 years, was diagnosed as having follicular mixed cell lymphoma in May, 1998.
  • He also had extranodal lymphoma involvement of the right parotid gland and bone marrow, as well as generalized lymphadenopathy.
  • After one course of CHOP chemotherapy, he developed paresis of the lower legs and was found to have a mass at the Th5-6 vertebrae by CT scan.
  • After four courses of CHOP chemotherapy followed by ESHAP chemotherapy and radiotherapy, he achieved complete remission, and has since been well.
  • Follicular lymphoma occurring among siblings is rare.
  • [MeSH-major] Lymphoma, Follicular / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Family Health. Humans. Male. Middle Aged. Nuclear Warfare. Prednisolone / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11452461.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2; VAP-cyclo protocol
  • [Number-of-references] 15
  •  go-up   go-down


29. Tanaka T, Araki T, Kasuya G, Fujino T, Makita K: [A malignant lymphoma (non-hodgkin lymphoma, follicular type) patient who achieved complete remission by radiochemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1931-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A malignant lymphoma (non-hodgkin lymphoma, follicular type) patient who achieved complete remission by radiochemotherapy].
  • She had suffered discomfort from that swelling since she had been diagnosed with erysipelas by a dermatologist she had visited 6 months before and received some medication.
  • Suspicious of a subcutaneous soft tissue tumor, we performed a biopsy, and histological examination of the lesion indicated malignant lymphoma (follicular lymphoma grade 2).
  • PET-CT (as of September, 2008) showed abnormal migration at the right inguinocrural and right external iliac lymph nodes.
  • In view of her age and the that rapid exacerbation, we considered chemotherapy (rituximab, cyclophosphamide, adriamycin, vincristine and prednisolone: R-CHOP) and involved field radiotherapy (IFRT) better to perform than 'watchful wait'.
  • PET-CT (as of November, 2008) after 3 courses of R-CHOP therapy showed abnormal migration had been significantly improved (complete remission on PET-CT) and completely disappeared in the right external iliac lymph nodes.
  • For long-term prognosis and prophylaxis of recurrence, we then added 2 courses of chemotherapy (rituximab alone) and IFRT (30 Gy/20 Fr) as radical therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Prednisolone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920404.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


30. Zinzani PL: Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol; 2005 Feb;32(1 Suppl 1):S4-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma: diagnosis, staging, natural history, and treatment strategies.
  • Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system.
  • Precise staging of NHL is a prerequisite for the selection of a suitable therapeutic regimen and influences the likelihood of its success.
  • Staging of lymphoma is traditionally conducted using tumor biopsy, imaging (X-ray, computerized tomography [CT], magnetic resonance imaging, lymphangiogram, gallium scan using 67 Ga citrate single photon emission CT [ 67 Ga-SPECT], or positron emission tomography), blood tests, bone marrow examination, and examination of cerebrospinal fluid.
  • Low- and high-grade lymphomas differ markedly in prognosis and response to treatment.
  • The management of NHL has been characterized by the increasing recognition that distinct subgroups of NHL respond differently to various therapeutic approaches.
  • In follicular lymphoma (FL), a successful approach has been to combine fludarabine with mitoxantrone (FM), resulting in an overall response rate of 89% (67% complete remission).
  • In an ongoing phase III trial in patients with untreated, advanced, low-grade follicular lymphoma, FM was compared with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) with or without rituximab.
  • Patients previously treated with FM achieved a significantly better complete remission rate (67% v 38%; P = .0013) and a better molecular remission (36% v 20%; P = .049) than patients previously treated with CHOP.
  • Following rituximab treatment, 88% of patients who had received FM achieved clinical and molecular remission compared with 70% who had received CHOP.
  • Strategies using various chemotherapy combinations, including innovative agents such as 90 Y-ibritumomab tiuxetan, show promise in the treatment of NHL, particularly indolent NHL, and hopefully will lead to an improvement in prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Vidarabine / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Neoplasm Staging. Prognosis. Radiopharmaceuticals / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786020.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / ibritumomab tiuxetan; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down






Advertisement